| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -2,994,992 |
| Depreciation and amortization | 257,907 |
| Amortization of right-of-use assets | 45,471 |
| Impairment of long-lived assets | 261,780 |
| Provision for credit losses | 73 |
| Stock-based compensation | 12,000 |
| Non-cash other operating activities | -147,842 |
| Accounts receivable | 123,209 |
| Inventories | -7,038 |
| Research and development tax incentive receivable | 189,654 |
| Other current assets | -338,794 |
| Accounts payable and accrued expenses | -567,109 |
| Long-term employee benefit liabilities | 15,120 |
| Operating lease liabilities | -57,886 |
| Net cash used in operating activities | -2,846,825 |
| Purchase of property and equipment | 70,401 |
| Net cash used in investing activities | -70,401 |
| Proceeds from issuance of common stock, net of issuance costs | 224,534 |
| Proceeds from issuance of common stock for warrants exercised, net of issuance costs | 3,333,631 |
| Net cash provided by financing activities | 3,558,165 |
| Effect of foreign exchange rates on cash and cash equivalents | -743 |
| Net increase (decrease) in cash and cash equivalents | 640,196 |
| Cash and cash equivalents at beginning of period | 1,019,909 |
| Cash and cash equivalents at end of period | 1,660,105 |
INTELLIGENT BIO SOLUTIONS INC. (INBS)
INTELLIGENT BIO SOLUTIONS INC. (INBS)